Figure 1: Primary culture of osteoblasts
Study and pharmacological modulation of bone metabolism.
After an osteoporotic hip fracture, one in three patients dies the following year due to derived complications. In those breaks, bone quality is deficient, which justifies the likeliness of a fracture and conditions the correct recovery of the patients. In the bone, the differentiation of mesenchymal stem cells to osteoblasts is equilibrated with their differentiation to adipocytes. The break of this balance is among the critical factors behind the loss of bone quality. This research line aims to identify factors (physical, chemical, or biological) that modulate the equilibrium between osteoblastogenesis and adipogenesis, and their potential use as biomarkers or therapeutic targets for either these complications or those other diseases with defective bone quality (osteoarthritis, arthritis, …)